Learn More


 
MBA Tools
MBA Glossary

 


Cubist Pharmaceuticals Inc - CBST - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

 

Cubist Pharmaceuticals Inc - SIC # 2834

Ticker Exchange SIC # Website Latest Ticker
CBST Nasdaq 2834 http://www.cubist.com/ 49.97 Stock Down -1.16

Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company:

Latest Headlines for Cubist Pharmaceuticals Inc

Gilead Presents Idelalisib Data - Jun 19th, 2013 9:00 am
Positive Data on Novartis' Jakavi - Jun 18th, 2013 2:55 pm
MannKind Completes Afrezza Studies - Jun 18th, 2013 12:30 pm
Encouraging Data on Novartis' Gilenya - Jun 14th, 2013 2:25 pm
Incyte's Jakafi Label Updated - Jun 13th, 2013 12:10 pm
SmithOnStocks Opines: June 9, 2013 - Jun 9th, 2013 8:25 pm
Incyte Presents Positive Jakafi Data - Jun 5th, 2013 2:35 pm
Encouraging data from Bristol-Myers - Jun 5th, 2013 9:10 am
Celgene Presents Data at ASCO - Jun 5th, 2013 9:00 am
MannKind Progresses on Afrezza - Jun 3rd, 2013 3:40 pm


View All Current Headlines >>

Bookmark and Share
facebooktwitter